Browse the evidence

Metabolic and bariatric surgery (MBS) is an effective means of durable weight loss, with sleeve gastrectomy being the most performed procedure, offering significant long-term weight loss and diabetes remission.

If lifestyle changes and medications aren't enough, consider metabolic and bariatric surgery (MBS). It offers the most durable weight loss, especially sleeve gastrectomy and gastric bypass. It's suitable for those with BMI >35 (or >30 with health issues). You must commit to lifelong monitoring and supplementation to prevent nutrient deficiencies.

Retatrutide and dual agonists achieved equivalent mean weight loss of -11.0 kg, surpassing GLP-1RAs which had a mean weight loss of -9.0 kg.

Practitioners can expect retatrutide and dual agonists to provide significant weight loss compared to GLP-1RAs.

Retatrutide excels at achieving ≥ 15% weight loss with an odds ratio of 54.6.

Retatrutide may be particularly effective for patients aiming for significant weight loss.

All obesity management medications (OMMs) showed significantly greater total body weight loss percentage (TBWL%) versus placebo.

Practitioners can consider OMMs as effective options for weight loss in adult patients.

Time-restricted eating resulted in a mean weight loss of -8.0 kg, while daily calorie restriction resulted in a mean weight loss of -6.3 kg after 12 months.

Both time-restricted eating and daily calorie restriction can lead to weight loss, but the choice may depend on individual preferences.

Participants in the TRE group experienced a significant body weight reduction of -3.56% by month 6 compared to controls.

TRE may be an effective weight loss strategy for adults with type 2 diabetes.

The low-calorie group lost significantly more weight than the low-fat group, with males losing 11.8 kg and females losing 8.2 kg in the low-calorie group compared to males losing 8.0 kg and females losing 3.9 kg in the low-fat group.

Practitioners may consider caloric restriction more effective for weight loss than a low-fat diet.

There was significantly greater loss of body fat in the low-calorie group compared to the low-fat group.

Caloric restriction may be more effective for reducing body fat than simply lowering fat intake.

Tirzepatide (TZP) caused greater weight loss than placebo (PBO) with a difference of -16.7 kg vs -8.3 kg (p<0.001).

Practitioners can consider TZP as an effective intervention for weight loss in obese patients.

Tirzepatide significantly reduced food intake compared to placebo.

Reducing food intake may enhance the effectiveness of weight loss strategies in obese individuals.

At 176 weeks, the mean percent change in body weight among participants who received tirzepatide was -12.3% with the 5-mg dose, -18.7% with the 10-mg dose, and -19.7% with the 15-mg dose, compared with -1.3% among those who received placebo.

Tirzepatide is effective for significant weight loss in individuals with obesity and prediabetes.

Three years of treatment with tirzepatide resulted in substantial and sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than that with placebo.

Tirzepatide is effective for long-term weight management and diabetes prevention.

Once-weekly subcutaneous semaglutide resulted in a mean weight change of -15.8% compared to -6.4% with once-daily subcutaneous liraglutide at 68 weeks.

Semaglutide may be more effective than liraglutide for weight loss in this population.

Participants had significantly greater odds of achieving 10% or more weight loss with semaglutide compared to liraglutide (70.9% vs 25.6%).

Semaglutide may offer a higher likelihood of significant weight loss compared to liraglutide.

Cagrilintide-semaglutide resulted in a mean percent change in body weight of -20.4% from baseline to week 68 compared to -3.0% with placebo.

Cagrilintide-semaglutide may be an effective treatment option for significant weight loss in adults with overweight or obesity.

Participants receiving cagrilintide-semaglutide were more likely to achieve weight-loss targets of 5%, 20%, 25%, and 30% or more compared to placebo.

Cagrilintide-semaglutide may help patients achieve significant weight-loss goals.

Participants receiving tirzepatide maintained a mean weight change of -5.5% from week 36 to week 88 compared to a 14.0% weight change with placebo (difference, -19.4%; P < .001).

Continued use of tirzepatide is effective for maintaining weight loss in adults with obesity.

89.5% of participants receiving tirzepatide maintained at least 80% of their weight loss during the lead-in period compared to 16.6% receiving placebo (P < .001).

Tirzepatide significantly improves the likelihood of maintaining weight loss in adults with obesity.

The overall mean weight reduction from week 0 to 88 was 25.3% for tirzepatide and 9.9% for placebo.

Tirzepatide leads to significantly greater weight loss compared to placebo over the study period.

Calorie restriction results in a significant decrease in waist circumference of -6.1±0.4 cm compared to a control group with a change of 0.9±0.5 cm after 24 months.

Practitioners can expect significant reductions in waist circumference with CR in non-obese adults.

Once-weekly treatment with tirzepatide 10 mg resulted in a mean change in body weight of -13.6% at week 52.

Tirzepatide 10 mg can be an effective option for weight reduction in this population.

Once-weekly treatment with tirzepatide 15 mg resulted in a mean change in body weight of -17.5% at week 52.

Tirzepatide 15 mg can be an effective option for weight reduction in this population.

87.7% of participants achieved body weight reductions of 5% or greater with tirzepatide 10 mg.

A significant majority of participants experienced clinically meaningful weight loss with tirzepatide 10 mg.

All intermittent fasting and continuous energy restriction diet strategies reduced body weight when compared with ad-libitum diet.

Intermittent fasting and continuous energy restriction can be effective strategies for weight loss in diverse populations.